Ipsen Investor Relations Material
Ipsen S.A. provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders and rare diseases. The company's products include Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell ad second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure and GH deficiency in adults; Increlex for growth failure in children and adolescents.
Key slides for Ipsen S.A.
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023